AUXESIS PHARMA

MEMORANDUM ON

AUXESIS PHARMA HOLDING AB (publ)

559195-6486

MARCH 2023

CONTENT

INTRODUCTION

AUXESIS PHARMA HOLDING AB (publ) is a public company focusing on medical research and Life Science on humans and animals.

The president of the company is Roar Adelsten, an entrepreneur, who has, over his years, focused on companies in these industries. The vast experience of Roar Adelsten makes it possible for him to find innovative objects and medical research with great potential.

Life Science is an expanding industry with a non-cyclical market. The growth potential is presently higher than in most other sectors. Hence an investment in AUXESIS PHARMA HOLDING AB (publ) gives access to a considerable growth potential.

The general assembly of AUXESIS PHARMA HOLDING AB (publ) has decided to sell in total 600.000 shares through an emission, which implies 10,4 % of the ownership.

In addition to the information given in this memo more detailed financial information can be found in the annual report 2021. More information of the companies can be found at the website; www.auxesis.se.

AUXESIS PHARMA

OUR HISTORY IN BRIEF

2016 After several years of research and testing, Acet Medica AB was established in 2016 to enable agreements with various research teams.

2018 CoxyPet Pharma AB was established to be able to enter the animal care sector.

2019 Auxesis Pharma Holding AB was founded, which is now the parent company of Acet Medica AB and CoxyPet Pharma AB.

ASA.P® - is a registered trademark in Sweden, EU and the US and will shortly be a registered trademark on global markets.

CoxyPet® - is a registered trademark in the EU and currently in a trademark registration process across other markets.

ACET MEDICA

ASA.P®

COXY PET

GLOBAL HEALTH CARE MARKET - OVERVIEW IN GENERAL

Life Science is defined to include products, techniques, equipments, methods and services in medical and clinical activity and biotechnology research.

However, the prevention and management of chronic illness is a growing challenge for health policy in OECD countries. Despite increasing rates of diseases such as asthma and diabetes, care for these conditions is often suboptimal. Annual eye exams are widely accepted as standard care for diabetics, yet only about half actually have their eyes checked.

Given today's treatment options for preventing acute asthma attacks, asthma sufferers should be effectively treated by their primary care providers.

Today, people enjoy longer and healthier lives. Partly as a result, population ageing, technological innovation and growing expectations for better coordinated and patientoriented health services will put pressure on health systems. Health expenditure is expected to absorb an increasing share of national income in all OECD countries.

The changing demographics of the world, with an increase in the elderly part of the population, signal a fundamental shift in the health care sector. As medicine and living standards have pushed the average age higher, demand for new solutions and remedies arises. This demand highlights the need for continuous research and development. Both the individual demand for professional health care services as well as the political will to address the growing health care problems is driving demand on a global level. While many sicknesses and diseases can be treated today, many challenges remain. While many areas of the world receive adequate treatment today, in many countries none is available.

From a market perspective there is a strong and growing worldwide demand. Access, knowledge and research are key factors to address these issues. And research is continuing to provide solutions – just one example; the improved treatment of children with acute lymphoblastic leukemia has dramatically reduced mortality rate through new clinical methods and improved treatment.

The provision, the quality and the distribution of medical care services around the globe vary. The distribution systems can be divided into two main channels. One is publicly funded, the other is privately held and based on the free market principles. In many countries both these channels exist side by side, for example as in Sweden and the US.

The fundamental question is what causes the quality of distribution. The answer is straightforward; it's about the political commitment to provide sufficient welfare levels. Society's ability to provide its inhabitants with excellent medical care is today a central political issue, which indicates the importance that people feel such services have on their lives.

Medical care services are always of public interest, also economic growth in countries such as China and India , with a more affluent and aging population, signals a growth in demand for adequate and advanced health care services. Less affluent countries, especially in Africa, have an obvious need for increased health care investments within some countries.

The demand for advanced medical care service is here to stay and will certainly increase. An investment in research and development in the area of human medicine will always provide a strongly positive return on investment if there are useful products, methods and techniques as its outcome. The global demand is there and will certainly increase.

The quality of healthcare, measured by the provision of recommended interventions or actual health outcomes, is improving in OECD countries.
Reflecting the initial results from the OECD Health Care Quality Indicators project; *Health at a Glance 2007* reports that, across OECD countries, only 10% of people hospitalized after a heart attack die within 30 days of being admitted to a hospital, down from 20% in the 1980s. And only 10% of patients admitted to a hospital following ischemic stroke die within 30 days, thanks to better treatment for dissolving blood clots and to the creation of new stroke units.
However, the prevention and management of chronic illness is a growing challenge for health policy in OECD countries. Despite increasing rates of diseases such as asthma and diabetes, care for these conditions is often suboptimal. Annual eye exams are widely accepted as standard care for diabetics, yet only about half actually have their eyes checked.

Given today's treatment options for preventing acute asthma attacks, asthma sufferers should be effectively treated by their primary care providers. Yet, on average, 6 out of 10 000 adults in OECD countries are admitted to hospitals for asthma every year. *Health at a Glance 2007* also shows considerable variation in the quality of healthcare across countries, with no country performing better than others on all measures.

Today, people enjoy longer and healthier lives. Partly as a result, population ageing, technological innovation and growing expectations for better coordinated and patient oriented health services will put pressure on health systems. Health expenditure is expected to absorb an increasing share of national income in all OECD countries..

Source: www.oecd.org. OECD Annual report 2008.

LIFE SCIENCE IN SWEDEN

The Life Science sector in Sweden has a proven track record of successful ventures. The unique and close co-operation between the academic world, industry and the health care sector has provided a nurturing environment for innovation and entrepreneurship.

A number of successful companies in the field bear witness to this success; Astra Zeneca, Pharmacia, Nobel Biocare, Elekta and Gambro with well known advances such as the implantable pacemaker, the artificial kidney, dental implant and drugs like Losec (treatment for peptic ulcers).

Sweden aims to be a leading life sciences nation. Life sciences contribute to improving health and quality of life of the population, ensuring economic prosperity, advancing the country as a leading knowledge nation and achieving the 2030 Agenda for Sustainable Development. This national strategy aims to strengthen the long-term competitiveness of Sweden as a life sciences nation.

The Government's life sciences strategy is intended for stakeholders with a mandate and ability to change conditions for life sciences in Sweden. Sector stakeholders primarily include universities and higher education institutions, government agencies, authorities responsible for health and social care services, companies operating in the life sciences area and public and private financiers of research and innovation.

Patients, care recipients, and health and social care staff are key in this context, and their experience and expertise Sweden's national life sciences strategy must be harnessed in the change process – but without burdening them or similar groups with responsibility for development at national level.

Broad collaboration is essential to enable Sweden to be a globally competitive life sciences nation. The transition to precision medicine in health and social care will require engagement from all stakeholders in the sector.

SYSTEM INNOVATION

System innovation is key to harnessing new digital opportunities and data use that will enable the delivery of effective, accessible, personalized and preventive health and social care services. Stakeholders in the life sciences sector have different assignments, clients and priorities, and work towards similar but somewhat different goals.
This gives the sector an inherent complexity, making collaboration and coordination more difficult. Stakeholders in the sector demonstrate strong engagement and a clear understanding that collaboration is key to achieving improvements. Collaboration is also important for achieving greater staff mobility and skills development throughout the sector.

Source: Sweden´s national life sciences strategy, Swedish government, november 2020.

MARKET REFLECTIONS

A key market in this context is the United States of America. Not only because of the aggregate income potential, but also because of the national competence in medical and biotechnology research and development, hence the vast majority in Nobel Prize winners. The US holds the medical and scientific leadership and have a significant impact on the global market.

The Food and Drug Administration (FDA) is responsible for protecting the public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices; and by ensuring the safety of our nation's food supply, cosmetics, and products that emit radiation. FDA is responsible for advancing the public health by helping to speed innovations that make medical products more effective, safe, affordable and by helping the public access the accurate, science-based information needed for medical products and foods to maintain and improve a healthy lifestyle.

Once accepted as an official/certified supplier by the FDA in the US, other national permits and acceptances/certifications are more easily acquired. Therefore an FDA approval is necessary for the US market, and possibly world wide. These facts have to be considered for future investments. Global prospects and investments require a potential to be successful in the US independently of production location.

"If you're looking for the next big thing, and you're looking where everyone else is, you're looking in the wrong place."
– Mark Cuban



ACET MEDICA AB

Acet Medica is a subsidiary to AUXESIS PHARMA HOLDING AB (publ). Ownership is 95,78%.

BUSINESS CONCEPT

Acet Medica AB will withhold prototype production and the license to produce and market our medical products in the Nordic countries in the start phase.

COXYPET PHARMA AB

CoxyPet Pharma AB is a subsidiary to AUXESIS PHARMA HOLDING AB (publ). 100% ownership.

BUSINESS CONCEPT

CoxyPet Pharma AB is a medical research company focusing on skin pain relief for the animal care and veterinary markets.

PHARMA AMERICA HOLDING INC

Pharma America is a Florida corporation established in 2020 by Bjorn Hansen. Pharma America Holding Inc is a development stage pharmaceutical company, also pursuing the licensing of other pharmaceutical products. The company has two subsidiaries, Intiem Inc. and Tribura Pharmaceuticals LLC.

BUSINESS CONCEPT

AUXESIS PHARMA HOLDING AB (publ) had an intention of collaboration with PHARMA AMERICA HOLDING INC for the US market. Their solutions combine medical developments in neuroscience, pharmacology and psychology. At the moment they are operative in other business areas, therefore the intention of collaboration is paused. However, AUXESIS PHARMA HOLDING AB (publ) owns 2% in PHARMA AMERICA HOLDING INC. Windeye Partners in New York has evaluated PHARMA AMERICA HOLDING INC to USD 20.000.000 (sept 2021).

Source: Windeye Partner, NY, Evaluation Sept 2021.

MARKET ANALYSIS

The global skin pain relief market is expected to reach USD 12.2 billion in 2027, with a growth rate of 5.2% CAGR (2020-2027). North America and Europe account for 68% of the global market. Figure below. Asia Pacific is expected to have the strongest growth rate in 2020, CAGR-2027 at 6.5%*.

Average annual growth rate (CAGR) is a measure of the growth rate an investment would have had if it grew at the same rate each year for a given period of time (expressed as a percentage). The measure assumes that all profits are reinvested at the end of each year.

There is a high demand globally for pain relief in case of stings and rashes from sunburn, wasp, mosquito bites, cold sores, stinging nettles, jellyfish, etc. The solutions available today are only reassuring – but ASA. P® offers quick pain relief. According to the WHO, 3.7 billion people under the age of 50 have cold sores (HSV-1). **

Infected with the virus Herpes simplex:

- 134.9 million people in Africa
- 82.2 million people in Asia Pacific
- 70.3 million in America
- 31.4 million in Europe
- 4.9 million in the Middle East

AUXESIS PHARMA HOLDING AB (publ) estimates to capture 3,7 % of the global market.Timeline is shown in the revenue figure. The prognosis is realistic with the market focus on the EU and USA.



Total revenue						
TSEK	2022	2023	2024	2025	2026	2027
Revenue	0	1845	18600	186000	2155000	3379500
EBT	0	405	4084	40840	478680	789020

*Source: alledmarketresearch.com and industryarc.com

**who.com

R & D

AUXESIS PHARMA HOLDING AB (publ) received SME-status by European Medicines Agency (EMA) in December 2021.

AUXESIS PHARMA HOLDING AB (publ) achieved SME-status of an enterprise as a “micro, small or medium size enterprise (SME)” for EMA related services by the European drug authority EMA.

A qualified accreditation for SME status means that the company in question is eligible to benefit for the provisions for administrative and financial assistance for SMEs laid down in regulation. I.e. Auxesis Pharma AB (publ) will easier gain access to advice and assistance from the EMA during the development phase of our products and the various EMA stages from product development to market launch.

The advice and assistance can be across; regulatory, financial and administrative services. The SME status can be extended annually for a year as soon as a report describing the operation and resource flow has been provided to EMA.

“Following your submission of 10/24/2021, please find below confirmation of the eligibility to benefit from the provisions for administrative and financial assistance for SMEs laid down in Regulation (EC) No 2049/2005. Any requests for assistance pursuant to Regulation (EC) No 2049/2005 should be addressed to the SME office. Please quote your EMA/SME number in any future correspondence with the Agency and your customer account number for all fee related enquiries/requests. Qualification of an enterprise as a micro, small or medium-sized enterprise (SME) for EMA related services only.”

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

IDENTIFICATION OF ENTERPRISE:

Name: AUXESIS PHARMA HOLDING AB (publ)
Size/Type of enterprise: Micro/Linked
EMA-SME number: EMA/SME/424/21
(to be quoted for all SME related enquiries)
Date of qualification: 12/05/2021
Expiry of SME status: 12/31/2022
Renewed SME status EMA January 2023
Customer account number: 0000610792
(to be quoted for all fee related enquiries/requests)

RESEARCH FOCUS AND STATUS

THE CHALLENGE

ASA is very sensitive to moisture. Therefore, the stabilisation process in a spray bottle is challenging. No one has so far managed to stabilise ASA. We have found a solution based on meta studies and previous studies investigations in the field.
We have also conducted a literature study of several thousands of published articles regarding ASA and various drug combinations with ASA, which have resulted in positive insights for the development team.

485.000 scientific reports according to acetylsalicylic acid have been studied during our own research. None has solved what must be solved to create the pain relief products we are conducting. The main challenge is stability.

R&D department is currently conducting the stability studies and the results are still positive. Stability studies are key measures to ensure the quality, safety, and efficacy of pharmaceutical products during the shelf life period. The purpose is to evaluate the effect of environmental factors on the stability.
To fulfill requirement for regulatory approval of the formulations the project plan experimental procedures and data acquisition and analysis will be performed according to Guidance on Stability testing of New Drug Substances and Products (CPMP/QWP/122/02, rev 1 corr, EMEA) and European Pharmacopoeia.

The primary aim of stability testing is to prevent the potential adverse effects caused by chemical and physical changes in pharmaceutical products. It is a compulsory requirement to provide data of stability tests to the regulatory agencies for the approval of a new product.

Secondly, stability testing will ensure the quality of the pharmaceutical product by evaluating chemical and physical changes during manufacturing and storage and provide the direct evidence to claim shelf life and storage condition.

Stability testing is a standardized procedure performed on drug substances and products and is employed at various stages of pharmaceutical product development. Accelerated stability testing (at relatively high temperatures and/or humidity) is used to determine the degradation products which may be found after long term storage. Testing under moderate conditions, for example those recommended for long-term shelf storage, at slightly elevated temperatures is used to determine the product's shelf life and expiration dates.

The R & D Department is now in the finalizing part of the products stability process. Stability has been accomplished, which was the greatest challenge in the beginning.

R&D STATUS AND PLANNED PROCESS



RX – PRESCRIPTION MEDICINE

In parallel with product development for the OTC market, AUXESIS is also developing solutions for patients where prescription medication is needed such as;

- Skin trauma connected to radiotherapy during cancer treatment
- Other skin and nerve trauma

PRODUCTS

There is currently no OTC / RX product on the market with immediate pain relief effect on skin.
The current substances available offer only soothing pain relief. ASA.P® offers immediate pain relief on skin from insect bites, skin burn, skin contact with poisonous plants, sunburn & rashes.

OTC, (over the counter), is a term that describes the entire marked of non-prescription medications. Analgesics is a collective term for pain-killing medications. Topical refers to “on the surface” and further indicates that this medication's route of entry into the body is through the skin, as opposed to being administered orally or intravenously.

The solution both resets the pain sensors in the skin and can be stored for long periods. Our formula creates pain relief within minutes and having a long shelf life.

It can be packaged for safe keeping in your medicine cabinet and applied as a gel, spray, salve, roll-on or bandage.

Its topical application ensures that only a negligible concentration of acetylsalicylic acid actually enters the bloodstream. Compared to common oral ingestions, ASA.P® creates little to no side effects. Most importantly, currently available solutions in the global market are only pain soothing, NOT pain removing, like ASA.P®.

COXYPET® - TARGETING VETERINARY HEALTHCARE

We will steer our research and development in the next stage towards the veterinary drug category.

- 1,5 billion cattle
- 28 million camels
- 600 million horses
- 960 million pigs
- 600 million cats
- 600 million dogs



The aim for CoxyPet Pharma AB is to develop pain elimination products for the animal care markets such as; veterinary, household pets, cattle industry, horseracing, camelrace, dograces etc.



coxy PET

ASA.P®

ASA.P®

ASA.P® - Local analgesic OTC medicine in various forms for application on skin

ASA.P® - The active substance acetylsalicylic acid has immediate effect

ASA.P® - A new method for Aspirin, but in liquid form

ASA.P® - Treatment for insect bites, herpes zoster, rashes, eczema etc

ASA.P® - Applied directly onto skin with immediate effect (3-4 minutes)

ASA.P® - Will not enter and mix in the bloodstream meaning no side effects

ASA.P® - A unique and profitable product for treatment of topical pain on skin

PRODUCTION

AUXESIS PHARMA HOLDING AB (publ) is the holder of research knowledge and all immaterial rights for the global market.

Production will be accomplished by a subsidiary, but only for prototypes, plus a production for geographically limited markets; ie Sweden and the Nordic countries. Products may also be produced by all license holders with specific regulations from AUXESIS PHARMA HOLDING AB (publ).

Production preparation is already accomplished for the need of a quick start. Contact and communications are involving a larger city in Sweden with all the support and logistics needed for the start-up if chosen as the final candidate for the factory and production. Consumer packaging, national and international regulations issues are identified and already under preparation. Commercial productions are estimated to start Q4 2023.

PRODUCT DEVELOPMENT STRATEGY

ASA.P® OTC

1st product
- **Tested dosage form**
- **Spray**

Combination product

New combinations and platforms of delivery
- **New active ingredients**
- **New combinations**
- **New forms of dosage**
- **New platforms of delivery**

ASA.P® RX
prescription medicine

New indications
- **Pain relief following radiotherapy**
- **Smallpox**
- **Atopic dermatitis**
- **Amputation (itching &pain)**
- **Non-melanoma skin cancer (itching&pain)**
- **Squamous cell carcinoma (pain)**
- **Lymphoma (itching)**

The first clinical trials of ASA.P® OTC will decide the following product development strategy and range extension.

AUXESIS PHARMA HOLDING AB (publ) SHARE CAPITAL INFO

AUXESIS PHARMA HOLDING AB (publ) has 5.156.324 registered shares.

There is convertible holders of a possible addition of 639.666 shares in 2024. Furthermore, the company decided to give the board mandate to a share issue of 600.000 shares at the annual meeting 10th of June 2022, until next annual meeting (2023). There are no differences in voting rights between existing shares.

MARKET LISTING

AUXESIS PHARMA HOLDING AB (publ) is not listed on the stock market. However, the plan is to get into one of the Swedish stock markets.

As a preparation, the company decided on the annual meeting the 10th of June 2022, to become a CSD-registered company. Euroclear will hold the shareholders´ register from december 2022. Stock market listing is estimated earliest to Q4 2023.

AUXESIS PHARMA HOLDING AB (publ) SHAREHOLDERS

The number of shareholders is over 200. The majority owner is the holder of 72,47 % of shares and votes. The remaining 27,53 % is owned by private individuals, and companies.

Holder per march 2023	Shares in %
Captigenics Capital AB	72,47
Roar Adelsten	7,0
Professor Moustapha Hassan	4,85
Others	15,69
Total	100,0

AUXESIS PHARMA HOLDING AB (publ) FINANCE FIGURES

Below table holds the financial figures for the company. Please notice that this is a research & development company without revenues from own businesses. However, there is an income during the year 2020. This is the value of shares in PHARMA AMERICA HOLDING INC, which were transferred to AUXESIS PHARMA HOLDING AB (publ) during the year 2020.

Period (TSEK)	Prel.	2201-2212	2101-2112	2001-2012	1902-1912
Turnover		0	0	1939	0
Number of Empl		1	1	0	0
EBITA		2219	5721	253	229
Balance		13894	13084	4696	1388
Equity		3502	2454	69	177
Solidity		25,3	18,8	1,5	12,8

Source: SYNA, Sweden. (SYNA is a credit evaluation company)

AUXESIS PHARMA HOLDING AB (publ) CREDIT RISK

Below graph shows the credit risk over time. The risk today is diminishing rapidly, down to a risk of 0,79 % for getting in financial trouble the coming twelve months.



Source: SYNA, Sweden

AUXESIS PHARMA HOLDING AB (publ) ORG. CHART

AUXESIS PHARMA HOLDING AB (publ)

Captigenics Capital AB	72,47%
Roar Adelsten	7,0%
Prof. Moustapha Hassan	4,85%
Others	15,69%

BOARD MEMBERS
AUXESIS PHARMA HOLDING AB (publ)

Rune Nordström
Roar Adelsten
Charlotta Larsson
Professor M. Hassan

ADVISORY BOARD
AUXESIS PHARMA HOLDING AB (publ)

Peter Hedberg
Lars Larsson
Ying Zhao
Professor M. Hassan
Rune Nordström

ACET MEDICA AB

AUXESIS PHARMA HOLDING AB (publ)	95,78%
Other	4,22%

COXYPET PHARMA AB

AUXESIS PHARMA HOLDING AB (publ)	100%

COMPANY EVALUATION

AUXESIS PHARMA HOLDING AB (publ) is now valued to 305 million SEK, 165 million SEK in May 2022 and 75 million SEK May 2020. Please view scenario valuation below. The new valuation is undertaken January 2023 by Fintegrity AB. The valuation is amongst others based on market potential and forecasted revenues.

One-Pager Scenario valuation

Valuation simulation

Mid value WACC	30,4%	Liquidity requirement	0,0%

AUXESIS PHARMA HOLDING AB (publ) — **Weigthed average cost of capital (discount rate)**

	26%	27%	28%	29%	30%	31%	32%	33%	34%
Enterprise value (EV)	**436 233**	**401 226**	**369 733**	**341 314**	**315 598**	**292 266**	**271 046**	**251 701**	**234 028**
Net debt(-)	-9 676	-9 676	-9 676	-9 676	-9 676	-9 676	-9 676	-9 676	-9 676
Liquidity requirement	-555	-555	-555	-555	-555	-555	-555	-555	-555
Share value (Equity value)	**426 002**	**390 995**	**359 502**	**331 083**	**305 367**	**282 035**	**260 815**	**241 470**	**223 797**

The value of 100% of AUXESIS PHARMA HOLDING AB (publ) amounts to 305 367 TSEK based on the scenario described in the complete report

Multiples	EV/EBITDA	EV/Sales
Listed companies		
Sun Pharmaceutical Industries Ltd.	28,85	5,24
Johnson & Johnson	14,33	4,37
GlaxoSmithKline plc	23,13	6,50
Pfizer Inc.	23,23	6,50
Sanofi	8,80	2,78
AstraZeneca PLC	25,49	5,22
Merck & Co., Inc.	13,47	4,84
Bayer Aktiengesellschaft	7,70	1,80
Average	**18,13**	**4,66**
Median	**18,73**	**5,03**
Auxesis Pharma (Avg 2023-2029)	1,88	0,93

Source: Yahoo Finance as of 2023-02-28

- **Enterprise Value (EV) in AUXESIS PHARMA HOLDING AB (publ) is calculated within the interval 234 028 – 436 233 TSEK with a direction value of 315 598 TSEK. Enterprise value refers to the value of the business, i.e. the value today of the future return that the business is expected to give rise to in the future, regardless of how one chooses to finance the company. The direction value of 315 598 TSEK is the best estimate of the value of the debt/cash free business for AUXESIS PHARMA HOLDING AB (publ) given the scenario described in the report.**
- **In order to obtain the value of the shares in the Company, interest-bearing debt, financial assets and liquidity requirements must be taken into account as of 2023-01-01.**
- **Considering the company's current net debt and liquidity requirements, the conclusion is that the direction value of 305 367 TSEK constitutes the best estimate of the share value for 100% of the shares in AUXESIS PHARMA HOLDING AB (publ) as of 2023-01-01, given the scenario described in the complete report. In the case of future investments and transactions in AUXESIS PHARMA HOLDING AB (publ), the company's net financial debt and liquidity requirements shall be taken into account as of the respective transaction date.**

MAJOR INVESTMENTS OF AUXESIS PHARMA HOLDING AB (publ)

MEDICAL RESEARCH, PATENTS, BRANDS ETC.

The major investments in the company is medical knowledge for specific medical research and product development. There are also costs for brand registration of ASA.P® as a brand in Europe, USA and other countries as; China, United Arab Emirates, Egypt, Australia, and New Zealand.

Patent application will be evaluated for monitoring May 2023, the latest. However, there is extensive time and effort invested in preparation. The company has transformed from privately held company to publicly.

AUXESIS PHARMA HOLDING AB (publ) is aiming for becoming a reconciliation company in June 2023. Avanza Bank is the emission Institute for handling this vs Euroclear.

The company has invested in a homepage (www.auxesis.se), with some interaction possibilities. The aim is to communicate with the public and its shareholders. The shareholders also have access to specifically addressed password protected information.

ACET MEDICA AB

A subsidiary to AUXESIS PHARMA HOLDING AB (publ).

Acet Medica AB was the start-up company for the research. After a few years the mother company bought all immaterial rights from Acet Medica AB, with research transferred to AUXESIS PHARMA HOLDING AB (publ), the mother company. All owners of Acet Medica AB were offered an exchange of shares/transferral of shares to the mother company. Accepted by all but four unresponsive individual shareholders with the ownership of 4,22 % of Acet Medica AB. Acet Medica AB is currently inactive with the aim to withhold prototype production and the license to produce and market our medical products in the Nordic countries in the start phase.

COXYPET PHARMA AB

A subsidiary to AUXESIS PHARMA HOLDING AB (publ).

The aim for the company is to develop pain elimination products for the animal care markets such as; veterinary, household pets, cattle industry, horseracing, camelrace, dograces. The market research result is showing a huge global market. Contacts have been made with expertise, research and development institutions.



TIMELINE

2016-2019

PATENT INVESTIGATION ACCOMPLISHED
LITERATURE STUDIES AND REVIEW OF META STUDIES
DOCUMENTATION WORK ACET MEDICA AB
(FTO) FREEDOM TO OPERATE-REPORT
USA PARTNERSHIP ESTABLISHED

2020

PROJECT PLAN
PROJECT GROUP
FINANCIAL BROKERAGE AGREEMENT SIGNED
EMA APPLICATION OF SME STATUS

2021

CAPITALIZATION
R&D CHEMICAL ANALYSIS AND MANUFACTURING CONTROL, FORMULA, STABILITY, TOXICITY, SCIENTIFIC ADVICE
LICENSE AGREEMENT SIGNED FOR THE AMERICAS
Q4 – EUROPEAN MEDICINES AGENCY APPROVES AUXESIS SME STATUS

2022

Q4 – PRE-CLINICAL TRIALS ONGOING WITH SEVERAL FORMULAS
Q4 – PRIOR ART IPR RESEARCH
Q4 –INTERNATIONAL TRADEMARK REGISTRATIONS FOR ASA.P®
Q4- FINALIZE PRE-CLINICAL TRIALS

2023

Q1 – MANUFACTURING FACILITY IN SWEDEN - PLANNING
Q1 – RENEWED SME STATUS EMA JANUARY 2023
Q1/Q2 – COMPLETION OF PRE-CLINICAL TRIALS – BASIC
Q3 /Q4 – CLINICAL TRIALS ON HUMANS START UP
Q4 – PLANNING FOR IPO

2024

COXYPET CLINICAL TRIALS AND DEVELOPMENT ENDS
– FIRST ANIMAL INDICATION

THE BOARD

ROAR ADELSTEN

CEO

Market economist and certified drug consultant. Roar Adelsten is the visionary founder of Auxesis Pharma Holding AB, Acet Medica AB and CoxyPet Pharma AB.



RUNE NORDSTRÖM

Chairman of the Board and Advisor

Strategic communication, branding, public affairs and business consulting.

PROFESSOR MOUSTAPHA HASSAN

Professor of Transplantation research

Director of the pre-clinical laboratory Karolinska Universitetssjukhuset, Sweden.

CHARLOTTA LARSSON

Board member

Long and broad global experience from leading positions within FMCG & OTC corporations; marketing, sales, strategy & business development.

KEY PEOPLE

LARS LARSSON, *MSc in management*

CFO

Long and broad experience from business management and business development.

YING ZHAO

Scientific research/Post Doc

Karolinska Universitetssjukhuset, Preklinis-ka Laboratoriet, Preclinical Imaging Facility (PIF).

PETER HEDBERG

Lawyer

Partner at Ramberg Advokater, Stockholm.
Expert in IP rights, specialised in areas of marketing, business law and dispute resolution.



NEW SHARE ISSUE

MEDICAL RESEARCH, EMA, PATENTS, BRANDS ETC.

AUXESIS PHARMA HOLDING AB (publ) plans to strengthen present investments and expand the portfolio with new ventures. The general assembly, on the annual meeting on 10th of June 2022, has therefore decided to raise at least 18-20 million SEK within the framework of an issue of new shares to investors.

Subscription

Issue price:	SEK 50-59 per share, depending on amount of shares
Number of shares:	Maximum 600 000 shares
Minimum subscription:	Minimum 500 shares
Company valuation:	305 000 000 SEK

DISCLAIMER

Any person who wishes to use this information, to purchase shares, from any country other than those within the European Union (EU), may not regard this, as either an offer or an invitation to buy or subscribe for shares. It is the responsibility of every person outside the EU, regardless of citizenship, and who wishes to buy shares, to ensure that the company, he or she, by making purchases, accepts Swedish law, regardless of where in the world the purchase will take place.

This information does not constitute a solicitation or offer, for anyone, to purchase or to subscribe for shares in any jurisdiction in which such offer or solicitation is or may be deemed unlawful.

The information herein can be changed without further notice and will not or cannot be used as an excuse for anyone to make complaints towards the company. Such a change cannot become subject to any judicial review, indictment or subpoena.

AUXESIS PHARMA

ACET MEDICA

COXY PET

AUXESIS PHARMA HOLDING AB (publ)

Visiting address:
Karolinska Institute Science Park
Fogdevreten 2A, SE-171 65, SOLNA

Postal address:
P.O.Box 3626, Regeringsgatan 63
SE-103 59, STOCKHOLM

+46 (0) 8 771 43 00

info@auxesis.se
auxesis.se